Inhibrx (NASDAQ: INBX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.800 | ||||||
REV | 929.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Inhibrx (NASDAQ: INBX) through any online brokerage.
Other companies in Inhibrx’s space includes: Immunovant (NASDAQ:IMVT), Vaxxinity (NASDAQ:VAXX), Humacyte (NASDAQ:HUMA), Immatics (NASDAQ:IMTX) and Tango Therapeutics (NASDAQ:TNGX).
The latest price target for Inhibrx (NASDAQ: INBX) was reported by SMBC Nikko on Wednesday, March 16, 2022. The analyst firm set a price target for 40.00 expecting INBX to rise to within 12 months (a possible 193.04% upside). 5 analyst firms have reported ratings in the last year.
The stock price for Inhibrx (NASDAQ: INBX) is $13.65 last updated May 27, 2022, 8:00 PM UTC.
There are no upcoming dividends for Inhibrx.
Inhibrx’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Inhibrx.
Inhibrx is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.